CSIMarket Company Name, Ticker, Suppliers, else..
 
Artelo Biosciences Inc   (NASDAQ: ARTL)
 
Price: $6.0400 $-0.18 -2.894%
Day's High: $6.34499979019165 Week Perf: 186.11 %
Day's Low: $ 5.97 30 Day Perf: 703.19 %
Volume (M): 27,361 52 Wk High: $ 19.91
Volume (M$): $ 0 52 Wk Avg: $5.16
Open: $6.25 52 Wk Low: $0.52



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 0
 Employees 7
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 8
 Capital Exp. (TTM) (Millions $) 0

Business Description


Artelo Biosciences Inc is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics targeting the endocannabinoid system for the treatment of various diseases and conditions. The company focuses on developing drugs that modulate the endocannabinoid system to address pain, inflammation, and cancer-related symptoms. Artelo's pipeline includes candidates for cancer-related anorexia and weight loss, opioid reduction in cancer patients, and arthritis. They aim to provide safe and effective treatment options to improve the lives of patients suffering from these conditions.


   Company Address: 505 Lomas Santa Fe Solana Beach 92075 CA
   Company Phone Number: 925-7049   Stock Exchange / Ticker: NASDAQ ARTL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABEO        1.35% 
BMRN        2.88% 
ISCO   -19.16%    
OVID      0% 
PFE        1.75% 
VRTX        0.82% 
• View Complete Report
   



Clinical Study

Evaluating Artelo Biosciences Promising Clinical Results Amidst Market Underperformance

Published Thu, Sep 4 2025 4:35 AM UTC

: This article examines the recent developments surrounding Artelo Biosciences, Inc., focusing on the company’s encouraging interim Phase 2 results for the treatment of Cancer Anorexia-Cachexia Syndrome (CACS) utilizing ART27.13. Despite these promising clinical outcomes, Artelo s stock performance has lagged behind market expectations and competitors, raising questions ...
Clinical Study

Progress in Novel Pharmacotherapies for Mood and Anxiety Disorders Leveraging Lipid Signaling Pathways

Published Tue, Jul 8 2025 2:52 PM UTC

The treatment of mood and anxiety disorders continues to present significant challenges, prompting ongoing research into novel therapeutic pathways. Traditional pharmacologic approaches, primarily selective serotonin reuptake inhibitors (SSRIs), have finite efficacy and are often accompanied by adverse effects that can compromise patient adherence. Recent advancements in lip...
Management Announcement

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Published Thu, Jun 26 2025 12:00 PM UTC

Artelo Biosciences: Navigating Financial Challenges Amid Promising Clinical DevelopmentsIntroductionArtelo Biosciences, Inc. (Nasdaq: ARTL) recently announced a private placement financing round that raised approximately $1.425 million. This capital injection comes at a time when the clinical-stage pharmaceutical company faces significant financial hurdles characterized by ...
Product Service News

Promising Phase 1 Data from CAReS Trial Demonstrates Safety and Efficacy of ART27.13 in Cancer-Related Anorexia

Published Mon, Dec 30 2024 7:37 PM UTC

: Artelo Biosciences has announced significant findings from its Phase 1 clinical trial (CAReS) evaluating ART27.13, an investigational treatment for cancer-related anorexia. The results indicate a favorable safety profile and highlight the potential therapeutic benefits of this agent, with a notable proportion of participants achieving stabilization or reversal of weight lo...
Product Service News

Artelo Biosciences, a trailblazer in the biopharmaceutical industry, continues to make significant strides ...

Published Wed, Nov 13 2024 1:30 PM UTC

Cutting-Edge Advances in Pain and Anxiety Management: Artelo Biosciences Groundbreaking Discoveries in Non-Opioid Treatments Artelo Biosciences, a trailblazer in the biopharmaceutical industry, continues to make significant strides in the development of novel non-opioid treatment options, showcasing their unwavering commitment to addressing some of the most prevalent challe...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.36
PEG (TTM) -

Financial Strength Current
Quick Ratio -
Working Capital Ratio 3
Leverage Ratio (MRQ) 0.29
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -118.06 $
Revenues (TTM) -
Cash Flow (TTM) 27.24 $
Cash -
Book Value 16.58 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,810,143
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.